Paul Lorigan

63.1k citations

330 papers · 12.8k indexed · 4 hit papers · h-index 58

Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers 95
- CAR-T cell therapy research 80
- Lung Cancer Research Studies 61
- Cutaneous Melanoma Detection and Management 56
Immunology top 1%
- Immunotherapy and Immune Responses 44
Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations 32
Cancer Research top 1%
Molecular Biology top 1%
- Melanoma and MAPK Pathways 83
Epidemiology
- Neuroendocrine Tumor Research Advances 39

Co-authors: James Larkin Caroline Robert Antoni Ribas Georgina V. Long Jean‐Jacques Grob Fiona Blackhall Ana Arance Omid Hamid
Cited by: Oncology Immunology Pulmonary and Respiratory Medicine
Partner nations: United Kingdom United States Germany

In The Last Decade

Paul Lorigan

321 papers receiving 12.5k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2019 Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
2017 Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
2017 Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
2016 Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

Peers

Countries citing papers authored by Paul Lorigan

Since Specialization

Citations

This map shows the geographic impact of Paul Lorigan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Lorigan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Lorigan more than expected).

Fields of papers citing papers by Paul Lorigan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Lorigan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Lorigan. The network helps show where Paul Lorigan may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Paul Lorigan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul Lorigan Line = papers co-authored together Paul Lorigan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cancer diagnoses, referrals, and survival in people with a learning disability in the UK: a population-based, matched cohort study Oliver Kennedy,Umesh Chauhan,Louise Gorman,Paul Lorigan,Samuel WD Merriel,Tjeerd van Staa,Alison K. Wright,Darren M. Ashcroft	2025	0
2	A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021 Khaylen Mistry,Polly Jeffrey,N. J. Levell,Oliver Kennedy,Kathryn Richardson,Paul Craig,Chloe J. Bright,Siobhan Taylor,John Ragan,Dimitrios Karponis,Joanna Pethick,Katrina Lavelle,Fiona E. McRonald,Steven J. Hardy,Sally Vernon,Paul Lorigan,Zoe C Venables	2025	0
3	Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations Sophia Kreft,Tommaso Bosetti,Rebecca Lee,Paul Lorigan	2025	0
4	Patterns of systemic treatment for melanoma: An insight on trends and costs between 2019–2023 from the English systemic anti-cancer therapy national database Tommaso Bosetti,Oliver Kennedy,Rebecca Lee,Avinash Gupta,Patricio Serra,Nadia Ali,Avanti Andhale,Sophia Kreft,Paul Lorigan	2024	1
5	Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN). Caroline Robert,Caroline Dutriaux,Felix Boakye Oppong,Michal Kiciński,Émilie Routier,Eve‐Marie Neidhardt,Xavier Durando,Barouyr Baroudjian,Philippe Saïag,Caroline Gaudy‐Marqueste,Paolo A. Ascierto,Ana Arance,Michelangelo Russillo,Jean‐Luc Perrot,Anne-Sophie Govaerts,Emanuel Bührer,Bastian Schilling,Mario Mandalà,Paul Lorigan,Alexander Christopher Jonathan Van Akkooi	2024	3
6	A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301). Georgina V. Long,Victoria Atkinson,Paolo A. Ascierto,Diwakar Davar,Omid Hamid,Caroline Robert,Marcus O. Butler,Reinhard Dummer,Christine Häfner,Muhammad Adnan Khattak,James Larkin,Paul Lorigan,Meredith McKean,Rino S. Seedor,Heather M. Shaw,Joe Stephenson,Yuan Yuan,Roma Patel,Piruntha Thiyagarajah,Dirk Schadendorf	2024	3
7	COLUMBUS-AD: Phase III Study of Adjuvant Encorafenib + Binimetinib in Resected Stage IIB/IIC BRAF V600-Mutated Melanoma Alexander C. J. van Akkooi,Axel Hauschild,Georgina V. Long,Mario Mandalà,Michal Kiciński,Anne-Sophie Govaerts,Isabelle Klauck,M. Ouali,Paul Lorigan,Alexander M.M. Eggermont	2023	11
8	Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study Patricio Serra-Bellver,Judith M. Versluis,H.K. Oberoi,Cong Zhou,Timothy D. Slattery,Yasir Khan,James R. Patrinely,Inês Pires da Silva,Clara Martínez-Vila,Natalie Cook,Donna M. Graham,Matteo S. Carlino,Alexander M. Menzies,Ana Arance,Douglas B. Johnson,Georgina V. Long,Lisa Pickering,James Larkin,Christian U. Blank,Paul Lorigan	2022	14
9	Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities Sharon H. Nahm,Richard Heywood,Sophia Callaghan,Patricio Serra-Bellver,Avinash Gupta,Tim Cooksley,Paul Lorigan	2022	5
10	Cost‐effectiveness of a policy‐based intervention to reduce melanoma and other skin cancers associated with indoor tanning* Martin Eden,Rob Hainsworth,Louisa G. Gordon,Tracy Epton,Paul Lorigan,Lesley E. Rhodes,Richard Marais,Adèle C. Green,Katherine Payne	2022	13
11	SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study Mario Mandalà,Paul Lorigan,Matilde De Luca,Andrea Bianchetti,Barbara Merelli,Anna Bettini,Lucia Bonomi,Sharon H. Nahm,Maria Grazia Vitale,Giorgia Negrini,Andrea Di Croce,Paolo A. Ascierto,Eliana Rulli,Carlo Tondini	2021	22
12	Sunbed Use among 11- to 17-Year-Olds and Estimated Number of Commercial Sunbeds in England with Implications for a ‘Buy-Back’ Scheme Louisa G. Gordon,Rob Hainsworth,Martin Eden,Tracy Epton,Paul Lorigan,Megan Grant,Adèle C. Green,Katherine Payne	2021	7
13	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancerbreakdown → Martin Reck,Alexander Luft,Aleksandra Szczęsna,Libor Havel,Sang-We Kim,Wallace Akerley,M. Catherine Pietanza,Yi‐Long Wu,Christoph Zielinski,Michael J. Thomas,Enriqueta Felip,Kathryn A. Gold,Leora Horn,Joachim G.J.V. Aerts,Kazuhiko Nakagawa,Paul Lorigan,Anne Pieters,Teresa Kong Sanchez,Justin Fairchild,David R. Spigel	2016	397
14	Discrepancies in Cancer Genomic Sequencing Highlight Opportunities for Driver Mutation Discovery Andrew Hudson,Tim Yates,Yaoyong Li,Eleanor W. Trotter,Shameem Fawdar,Phil Chapman,Paul Lorigan,Andrew V. Biankin,Crispin Miller,John Brognard	2014	27
15	A meta-analysis of randomized, controlled trials in metastatic melanoma establishes progression-free survival as a surrogate for overall survival Keith T. Flaherty,S J Lee,Reinhard Dummer,Axel Hauschild,Michael Hennig,Guoxian Long,Paul Lorigan,Corentin Robert,Dirk Schadendorf	2013	1
16	Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma María Romina Girotti,Malin Pedersen,Berta Sanchez‐Laorden,Amaya Virós,Samra Turajlic,Dan Niculescu‐Duvaz,Alfonso Zambon,John Sinclair,Andrew Hayes,Martin Gore,Paul Lorigan,Caroline J. Springer,James Larkin,Claus Jørgensen,Richard Marais	2012	272
17	Safety and pharmacokinetics of first-line amg 479 (mab to igf1r) or amg 102 (mab to hgf/sf) with platinum-based chemotherapy in extensive-stage small cell lung cancer (sclc) Paul Lorigan,J.C. Soria,Joan Stephenson,Alpesh M. Maru,R. Gervais,Mingyu Zhu,Ian McCaffery,Yi Jiang,Jesse McGreivy,Bonnie S. Glisson	2010	6
18	Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study Paul Lorigan,Jaap Verweij,Zsuzsa Pápai,Sjoerd Rodenhuis,Axel Le Cesne,Michael Leahy,John Radford,M. M. Van Glabbeke,Anne Kirkpatrick,Pancras C.W. Hogendoorn,Jean‐Yves Blay	2007	192
19	Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: A STBSG-EORTC trial Axel Le Cesne,Ian Judson,John Radford,Jean‐Yves Blay,A. van Oosterom,Sjoerd Rodenhuis,Paul Lorigan,ED Di Paola,José Jimeno,Jaco J. Verweij	2000	9
20	Total CD34 yield and CFU-GM as mobolisation and subsequent engraftment after high dose chemotherapy. Daniel Epurescu,S Scholey,RJ Hinchliffe,Jennifer L. Peel,Daniel A. Jones,Elisabeth Vandenberghe,AJ Vora,Paul Lorigan	1999	64

About Paul Lorigan

Paul Lorigan is a scholar working on Oncology, Immunology and Molecular Biology, having authored 330 papers that have together received 12.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (95 papers), Melanoma and MAPK Pathways (83 papers), CAR-T cell therapy research (80 papers), Lung Cancer Research Studies (61 papers), Cutaneous Melanoma Detection and Management (56 papers), Immunotherapy and Immune Responses (44 papers), Neuroendocrine Tumor Research Advances (39 papers) and Lung Cancer Treatments and Mutations (32 papers). The work is most often cited by research in Oncology (9.6k citations), Immunology (2.5k citations) and Pulmonary and Respiratory Medicine (2.6k citations). Paul Lorigan has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include James Larkin, Caroline Robert, Antoni Ribas, Georgina V. Long, Jean‐Jacques Grob, Fiona Blackhall, Ana Arance, Omid Hamid, Mark R. Middleton and Matteo S. Carlino.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact